Don’t Ignore This Market Rotation: Jim Cramer’s Views on Intel, Vertiv, TSMC, and More

10. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was among the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation. Cramer highlighted the company’s unsuccessful trial, as he remarked:

Finally, there’s Regeneron, which got blasted by a poor result on a metastatic melanoma cancer trial. I, along with many others, thought that this trial would succeed. You can’t buy a drug stock that falls that much on the first day of the decline. Most analysts seem to have keyed on this drug to recommend the stock. It’s damaged. There could be some more downgrades.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. A caller asked for Cramer’s thoughts on the company during the April 9 episode. The Mad Money host responded:

I think Regeneron, I think Leonard Schleifer’s doing an unbelievable job. I think the stock’s breaking out here, I really do. I mean, I looked at it for the Charitable Trust, that and Amgen, we bought another stock, but those are the two I really like.